World's Best Scientists 2026 revealed!
Christopher D.M. Fletcher

Christopher D.M. Fletcher

Award Badge
Best Scientists
2025

D-Index & Metrics

Best Scientists

D-Index
172
Citations
128527
World Ranking
803
National Ranking
484

Medicine

D-Index
176
Citations
134234
World Ranking
415
National Ranking
250

Research.com Recognitions

  • 2025 - Research.com Best Scientists Award

Overview

Christopher D.M. Fletcher was affiliated with Brigham and Women's Hospital in the United States. Their research work focused predominantly on medicine, with a significant number of publications within the subfields of pulmonary and respiratory medicine, rheumatology, oncology, pathology and forensic medicine, and surgery.

The scientist contributed extensively to the study and treatment of various tumor types and cancers. Key research topics in their body of work included:

  • Sarcoma diagnosis and treatment
  • Vascular tumors and angiosarcomas
  • Soft tissue tumor case studies
  • Urologic and reproductive health conditions
  • Lymphoma diagnosis and treatment
  • Bone tumor diagnosis and treatments
  • Cardiac tumors and thrombi

Christopher D.M. Fletcher authored numerous papers published in respected journals. Notable recent papers include:

  • "A Novel SS18-SSX Fusion-specific Antibody for the Diagnosis of Synovial Sarcoma," 2020, The American Journal of Surgical Pathology
  • "Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities," 2021, Cancer
  • "Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts," 2021, ESMO Open
  • "Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology," 2020, PubMed
  • "Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor," 2023, Journal of Clinical Oncology

Their collaborative work frequently involved coauthors such as Jason L. Hornick, Brendan C. Dickson, David Papke, Lynette M. Sholl, and William J. Anderson, with whom they shared multiple publications.

Christopher D.M. Fletcher's research was published primarily in venues including:

  • The American Journal of Surgical Pathology
  • Modern Pathology
  • Histopathology
  • Blood
  • Laboratory Investigation

The scientist's work contributed to a substantial number of publications addressing challenging areas in medical research and clinical guidelines, highlighting an interdisciplinary approach spanning diagnostics, treatment protocols, and tumor pathology. Christopher D.M. Fletcher passed away, and their work remains a reference in multiple areas of oncologic and pathologic medicine.

Best Publications

  • Diagnosis of gastrointestinal stromal tumors: A consensus approach.

    Christopher D.M. Fletcher;Jules J. Berman;Christopher Corless;Fred Gorstein

  • Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

    George Daniel Demetri;Margaret von Mehren;Charles D. Blanke;Annick Diane Van Den Abbeele

  • Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

    George D Demetri;Allan T van Oosterom;Christopher R Garrett;Martin E Blackstein

  • PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors

    Michael C. Heinrich;Christopher L. Corless;Anette Duensing;Laura McGreevey

  • Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor

    Michael C. Heinrich;Christopher L. Corless;George D. Demetri;Charles D. Blanke

  • Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

    Winette T A Van Der Graaf;Jean Yves Blay;Sant P. Chawla;Dong Wan Kim

  • Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033

    Charles D. Blanke;Cathryn Rankin;George D. Demetri;Christopher W. Ryan

  • Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT

    Charles D Blanke;George D Demetri;Margaret von Mehren;Michael C Heinrich

  • Differentiation and reversal of malignant changes in colon cancer through PPARgamma.

    Pasha Sarraf;Elisabetta Mueller;Daniel Jones;Frederick J. King

  • KIT activation is a ubiquitous feature of gastrointestinal stromal tumors.

    Brian P. Rubin;Samuel Singer;Connie Tsao;Anette Duensing

  • Terminal Differentiation of Human Breast Cancer through PPARγ

    Elisabetta Mueller;Pasha Sarraf;Peter Tontonoz;Peter Tontonoz;Ronald M. Evans;Ronald M. Evans

  • NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines.

    George D. Demetri;Robert S. Benjamin;Charles D. Blanke;Jean Yves Blay

  • The evolving classification of soft tissue tumours – an update based on the new 2013 WHO classification

    Christopher D M Fletcher

  • WHO classification of soft tissue tumours: an update based on the 2013 (4th) edition.

    Vickie Y. Jo;Christopher D.M. Fletcher

  • Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases.

    Cheryl M Coffin;Jason L Hornick;Christopher D M Fletcher

  • Molecular Correlates of Imatinib Resistance in Gastrointestinal Stromal Tumors

    Michael C. Heinrich;Christopher L. Corless;Charles D. Blanke;George D. Demetri

  • Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor

    Michael C. Heinrich;Robert G. Maki;Christopher L. Corless;Cristina R. Antonescu

  • PD-L1 EXPRESSION IS CHARACTERISTIC OF A SUBSET OF AGGRESSIVE B-CELL LYMPHOMAS AND VIRUS-ASSOCIATED MALIGNANCIES

    Benjamin J. Chen;Bjoern Chapuy;Jing Ouyang;Heather H. Sun

  • Functional annotation of a full-length mouse cDNA collection

    J. Kawai;A. Shinagawa;K. Shibata;M. Yoshino

  • STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications

    David A. Tuveson;Nicholas A. Willis;Tyler Jacks;Tyler Jacks;James D. Griffin

Frequent Co-Authors

Jason L. Hornick
Jason L. Hornick Brigham and Women's Hospital
George D. Demetri
George D. Demetri Dana-Farber Cancer Institute
Jonathan A. Fletcher
Jonathan A. Fletcher Brigham and Women's Hospital
Paola Dal Cin
Paola Dal Cin Harvard Medical School
Cristina R. Antonescu
Cristina R. Antonescu Memorial Sloan Kettering Cancer Center
Fredrik Mertens
Fredrik Mertens Lund University
Thomas Mentzel
Thomas Mentzel Friedrich Schiller University Jena
Samuel Singer
Samuel Singer Memorial Sloan Kettering Cancer Center
Eduardo Calonje
Eduardo Calonje St Thomas' Hospital
Nils Mandahl
Nils Mandahl Lund University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative pathways in healthcare can open doors to fulfilling careers beyond a traditional MD. Many students consider nursing programs due to flexible options and strong job prospects. For those looking to fast-track their careers, consider the cheapest direct entry msn programs available online for non-nurses. These programs allow career changers to quickly enter advanced nursing roles without prior nursing credentials.

Admission barriers can be a concern. If you are seeking accessible options, some of the easiest nursing programs to get into offer flexible entry requirements, making it simpler for applicants from diverse backgrounds to begin their journeys in nursing.

Beyond clinical care, medical billing and coding is a vital field that supports the healthcare industry. Those drawn to administrative or technical roles should consider medical billing and coding online schools that provide quality training with financial aid options.

Lastly, for prospective nursing students concerned about entrance exams, there are nursing schools that don't require teas or HESI exams, further broadening access to nursing education.

Best Scientists Citing Christopher D.M. Fletcher

Recently Published Articles